2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.
Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphoma.
In the trial, 102 patients were treated with lisocabtagene maraleucel (JCAR017; liso-cel). Abramson states that every patient reached the 6-month time point or beyond, so physicians have mature and exciting data. In the entire patient population, researchers are finding an overall response rate of 75% with a complete remission rate of 55%. These are heavily pretreated patients, states Abramson. All patients had at least 2 prior lines of therapy.
Of these high-risk patients, 70% have chemotherapy-refractory disease, 20% have double-hit lymphoma, about half of patients have never achieved a complete remission, and 40% have had a prior stem cell transplant, most of which were autologous.
This compares favorably to any other conventional therapy, but the most important question is durability of remissions in large-cell lymphoma. There was a high proportion of durable remissions, says Abramson. Forty percent of patients are responding 6 months later.